Tenon Medical (TNON) Q1 2026 earnings review
YoY Growth Remains Strong, But Sequential Momentum Stalls
Tenon Medical reported strong year-over-year progress with Q1 2026 revenue surging 90% to $1.4 million and gross margins expanding 24 percentage points to 68.5%. However, beneath the bullish YoY narrative, sequential momentum has stalled. Revenue dipped slightly from Q4 2025's $1.5 million, and operating expenses crept back up to $4.2 million. This combination widened the net loss sequentially to $3.5 million. The company successfully closed a $4.3 million convertible note to extend its cash runway, but the lack of formal forward guidance and the sequential revenue deceleration raise questions about the immediate adoption curve of the newly launched SImmetry+ system.
🐂 Bull Case
Gross margin reached an impressive 68.5% (up from 44.5% a year ago), demonstrating that Tenon's manufacturing base can achieve highly profitable unit economics as production volume overhead is absorbed.
The successful integration of the SImmetry+ system alongside the flagship Catamaran system is successfully transforming Tenon into a multi-solution provider, expanding its total addressable market to include lateral approach procedures.
🐻 Bear Case
Despite management's optimism surrounding the SImmetry+ rollout, Q1 2026 revenue of $1.4M was a step backward from the $1.5M achieved in Q4 2025, suggesting a potentially choppy adoption curve.
With Q1 net losses expanding sequentially to $3.5M, the company was forced to introduce $3.5M in convertible note liabilities to the balance sheet, generating $176K in new interest expense for the quarter.
⚖️ Verdict: ⚪
Neutral. While YoY metrics look spectacular on a percentage basis, the absolute dollar figures reveal a business that has temporarily plateaued sequentially while expenses continue to outpace gross profit by a significant margin.
Key Themes
Portfolio Expansion to Multi-Approach Capabilities
The addition of the SImmetry+ SI Joint Fusion System is a critical growth catalyst. By offering both lateral (SImmetry+) and inferior-posterior (Catamaran) surgical approaches, the sales team can now cater to a much broader range of surgeon preferences, removing a key historical bottleneck to adoption.
Gross Margin Stabilization
Gross margins are stabilizing near the 70% threshold. At 68.5% in Q1 2026, up 24 points YoY, the company is proving its thesis that higher top-line revenue will quickly absorb fixed production overhead. If revenue growth resumes, gross profit flow-through will be substantial.
Aggressive Physician Training and Center of Excellence
Adoption is directly correlated to training. Tenon hosted 21 physicians in targeted sessions in Q1 (following 24 in Q4 2025) and recently opened a new Center of Excellence Training Center in Tampa, FL, to accelerate onboarding in the Eastern Region.
Sequential Revenue Contradicts Growth Narrative
Management cites 'early returns on the strategy' and 'commercial momentum,' yet revenue fell from $1.5M in Q4 2025 to $1.4M in Q1 2026. If the SImmetry+ alpha launch 'exceeded all expectations' in Q4, the lack of sequential top-line growth in Q1 raises red flags about seasonality or plateauing utilization among early adopters.
Operating Expense Creep
During the Q4 call, management suggested the $3.9M OpEx level was a 'good baseline' for modeling. However, Q1 2026 OpEx immediately jumped to $4.2M, driven largely by Sales & Marketing expenses ($1.86M) to support the SImmetry+ rollout. This operating deleverage widened the net loss sequentially.
Lack of Forward Guidance
Management continues to withhold specific revenue or margin guidance for the fiscal year. Given the early stage of commercialization, the lack of management commitments leaves investors blind to expected cash burn and run-rate projections for the remainder of 2026.
Fortification of Intellectual Property
Tenon secured multiple Notices of Allowance from the USPTO in Q1, further defending its technology stack. The portfolio now boasts 29 issued U.S. patents and 9 international patents, providing a deep protective moat around both the Catamaran and SImmetry+ architectures against larger orthopedic competitors.
Other KPIs
Up from $3.8M at year-end 2025. This increase was purely driven by the $4.3M gross proceeds from the senior convertible note private placement in March 2026. Without this financing, the company would have ended the quarter critically low on cash.
Reversing from zero. The company operated entirely debt-free at the end of 2025. The introduction of the convertible note now saddles the P&L with interest expenses, a new headwind for achieving net profitability.
Accelerating. S&M increased from $1.65M in Q1 2025 to $1.86M in Q1 2026. This reflects the aggressive commercial expansion, new hires in the Eastern Region, and the costs associated with the SImmetry+ launch.
Key Questions
Sequential Revenue Disconnect
With the full commercial integration of SImmetry+ and the addition of 21 newly trained physicians in Q1, why did top-line revenue decline sequentially from $1.5M in Q4 2025 to $1.4M in Q1 2026?
Operating Expense Trajectory
Management previously noted Q4's $3.9M OpEx as a solid baseline for 2026, yet Q1 came in at $4.2M. Should investors view $4.2M as the new quarterly floor as Eastern Region sales leadership expands?
Convertible Note Dynamics
Can you provide more color on the conversion terms of the new $4.3M senior notes, and what metrics would trigger conversion versus repayment?